Navigation Links
CuraGen Reports Second Quarter 2009 Financial Results
Date:7/31/2009

p>

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to CuraGen's net cash at the closing of the CuraGen-Celldex merger, the expected aggregate and per share purchase price for CuraGen in the merger, the proposed settlement of the shareholder class action lawsuits, development opportunities for CR011 in breast cancer and melanoma and the expected timing for presenting updated data for the CR011 breast cancer study, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including the following: the CuraGen-Celldex merger may not be completed in the expected timeframe or at all; the settlement agreement may not be approved; net cash at closing of the merger may differ from CuraGen's estimates due to a number of factors, including higher than anticipated legal and advisory fees and a delay in the closing of the merger; any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources; the success of competing products and technologies; CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform; technological uncertainty and product development risks; product
'/>"/>

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
2. CuraGen Reports Third Quarter 2008 Financial Results
3. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
4. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
5. CuraGen to Present at the BIO CEO & Investor Conference
6. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
7. CuraGen Corporation Receives Notification from NASDAQ
8. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
9. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
10. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
11. CuraGen Appoints Clinical Oncologist as VP of Medical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... element of surprise has been a major advantage of ... Until now, epidemiologists had nothing to measure that might ... suboptimal responses to both the H1N1 pandemic of 2009 ... http://photos.prnewswire.com/prnh/20141121/160242 That virus advantage ... structural changes have been found that invariably to date ...
(Date:11/21/2014)... , November 21, 2014 , ... comercial   Mariano Rodríguez es elegid vicepresidente ... KLOX está en marcha para comenzar de forma ... de heridas de reciente aprobación en Europa   , ... se complace al anunciar los siguientes nombramientos: ...
(Date:11/21/2014)... (PRWEB) November 19, 2014 The science ... lives was shared with more than 200 primary students ... students from the University of Otago Physics Department and ... The Otago students, members of the university’s OSA/SPIE Student ... in early September, giving children from small, rural schools ...
(Date:11/21/2014)... Los Angeles, CA (PRWEB) November 20, 2014 ... “A Short Walk to the Other Side” ... was an “Award-Winning Finalist in the “Fiction: Short Story” ... . , Jeffrey Keen, President and CEO of USA ... entries from mainstream and independent publishers, including Simon & ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4
... VEENENDAAL, The Netherlands, June 2 ... today announced the creation,of an exclusive partnership and ... for an undisclosed sum. The two companies, headquartered ... the combination,will strengthen Nucletron,s position as global leader ...
... The American Institute of Aeronautics and Astronautics ... top emerging aerospace technologies. Developed by AIAA,s ... following: 1. "Greener Aviation" Technologies including emission ... the Federal Aviation Administration,s Continuous Low Emissions, Energy ...
... First Randomized Trial to Demonstrate Superior Clinical Benefit in Relapsed/Refractory Aggressive NHL , ... to treat Analysis results per FDA agreed upon Statistical Analysis Plan , ... Significant Increase in Complete Remission Rates 20% vs. 5.7%; p=0.021 ... Rate 37.1% vs. 14.3%; p=0.003 , ...
Cached Biology Technology:Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 2Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 3AIAA names top ten emerging aerospace technologies of 2009 2Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 2Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 3Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 4Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 5
(Date:11/6/2014)... paper from a team of Florida State University biologists ... could adapt to and survive environmental swings such as ... latest issue of the journal The Plant Cell ... DNA and proteins) is organized in a cell and ... are turned on and others are turned off. , ...
(Date:11/6/2014)... - Insilico Medicine, Inc, a Baltimore-based bioinformatics company ... diseases announced a research collaboration with the international ... Inc (OTC: CSBR). , "There are many companies ... Champions Oncology,s TumorGraft technology is unique in a ... experimentally generating vast amounts of valuable data. Our ...
(Date:11/5/2014)... great diversity in their ability to identify scents and ... in their perceptual evaluation of odors, with women outperforming ... , Sex differences in olfactory detection may play a ... to one,s perception of smell, which is naturally linked ... has been suggested to be cognitive or emotional, rather ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2
... University of Copenhagen lead the way for future monitoring of ... samples to keep track of fish and whales in the ... local fish and whale faunas and combat traditional fishing methods. ... PLOS ONE . "The new DNA-method means that ...
... political targets to significantly reduce and halt biodiversity loss. ... setting up of new targets for 2020. In addition, ... been incorporated in several global and the EU agendas ... a critical review of the existing and emerging biodiversity ...
... the political targets to significantly reduce and halt biodiversity ... the setting up of new targets for 2020. In ... has been incorporated in several global and the EU ... requires a critical review of the existing and emerging ...
Cached Biology News:New DNA-method tracks fish and whales in seawater 2Biodiversity conservation depends on scale: Lessons from the science-policy dialogue 2Biodiversity conservation depends on scale: Lessons from the sience-policy dialogue 2
The Zymo-Spin PI Fast-Spin column features durable polypropylene construction and is the same column featured in the His-Spin Protein Miniprep. Capacity is 800 l....
X-gal,1g...
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
... Quantities to Kilograms, Multiple ... Special amino acids and their derivatives, ... AMC, aldehyde, CMK, Purity from ... Chromogenic/Flurogenic Substrates, Solid Phase/Solution/Segment Coupling ...
Biology Products: